Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about JOHNSON & JOHNSON
02/19JOHNSON & JOHNSON : ERLEADA, a Next-Generation Androgen Receptor Inhibitor, Gran..
AQ
02/19JOHNSON & JOHNSON : How Johnson & Johnson Is Doing Its Part to Tackle the Worldw..
AQ
02/18OUTLOOK 2018 : A mother channels a loss unlike any other into a force to help ot..
AQ
02/18ABBVIE : Stocks’ Win Streak Extends to Six Days
AQ
02/16JOHNSON & JOHNSON : Stocks stretch winning streak to 6 days despite turbulence
AQ
02/16JOHNSON & JOHNSON : New tremfya® (guselkumab) data demonstrates long-term skin c..
PU
02/16THE KLEIN LAW FIRM : Reminds Investors of an Investigation Concerning Possible V..
BU
02/16EAT.MOVE.CONNECT. TIP : New website offers personalized cancer info, support
AQ
02/16JOHNSON & JOHNSON : Consumer presents new scientific research at 2018 american a..
PU
02/16JOHNSON & JOHNSON : - ERLEADA, a Next-Generation Androgen Receptor Inhibitor Gra..
AQ
02/16JOHNSON & JOHNSON : williams, ronald a
PU
02/16JOHNSON & JOHNSON : washington, a. eugene
PU
02/16JOHNSON & JOHNSON : mulcahy, anne m
PU
02/16JOHNSON & JOHNSON : mcclellan, mark b.
PU
02/16JOHNSON & JOHNSON : davis, d scott
PU
More most relevant news
All news about JOHNSON & JOHNSON
02/19JOHNSON & JOHNSON : ERLEADA, a Next-Generation Androgen Receptor Inhibitor, Gran..
AQ
02/19JOHNSON & JOHNSON : How Johnson & Johnson Is Doing Its Part to Tackle the Worldw..
AQ
02/18OUTLOOK 2018 : A mother channels a loss unlike any other into a force to help ot..
AQ
02/18ABBVIE : Stocks’ Win Streak Extends to Six Days
AQ
02/16JOHNSON & JOHNSON : Stocks stretch winning streak to 6 days despite turbulence
AQ
02/16JOHNSON & JOHNSON : New tremfya® (guselkumab) data demonstrates long-term skin c..
PU
02/16THE KLEIN LAW FIRM : Reminds Investors of an Investigation Concerning Possible V..
BU
02/16EAT.MOVE.CONNECT. TIP : New website offers personalized cancer info, support
AQ
02/16JOHNSON & JOHNSON : Consumer presents new scientific research at 2018 american a..
PU
02/16JOHNSON & JOHNSON : - ERLEADA, a Next-Generation Androgen Receptor Inhibitor Gra..
AQ
More news
Sector news : Pharmaceuticals - NEC
02/19BASF to face millions in extra costs in UK each year from Brexit - Handelsbla..
RE
02/19UK shares retreat as Reckitt disappoint
RE
02/19Reckitt shares sink on missed profit, vague outlook
RE
02/19NOVARTIS : Correction to Novartis CEO story
DJ
02/19Stronger European Earnings Augur More M&A, Higher Dividends
DJ
02/19AstraZeneca's immunotherapy drug wins key lung cancer approval
RE
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/19Healthcare In Transition 
02/19YOUR DAILY PHARMA SCOOP : AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Ce.. 
02/19Why Stryker Will Likely Continue Delivering Strong Growth 
02/18RETIREMENT STRATEGY : How To Have Enough And Which Stocks To Own 
02/18THERAVANCE BIOPHARMA : Johnson & Johnson Deal Looks Solid 
02/17STOCKS TO WATCH : Retail Heavyweights To Center Stage 
Qtime:0
Financials ($)
Sales 2018 81 103 M
EBIT 2018 24 826 M
Net income 2018 19 539 M
Debt 2018 11 371 M
Yield 2018 2,72%
P/E ratio 2018 18,47
P/E ratio 2019 17,26
EV / Sales 2018 4,55x
EV / Sales 2019 4,19x
Capitalization 358 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 151 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572
AMGEN3.23%133 277